Use of Neratinib in HER2-Positive Breast Cancer

(2:18)

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

(1:19)

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

(1:41)

Dr. Tripathy Discusses Neratinib in HER2+ Breast Cancer

(1:20)

Neratinib in MBC with HER2 Activating Mutations

(6:46)

Dr. Dang on Neratinib in Patients With HER2+ Breast Cancer

(1:9)

Neratinib in HER2+ Breast Cancer

(9:35)

Dr. Isaacs Discusses the Role of Neratinib in HER2+ Breast Cancer

(1:8)

ELEANOR: real-world use of neratinib in HER2+, early breast cancer

(2:34)

Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

(52)

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancer

(1:51)

The Emerging Role of Neratinib in HER2+ MBC

(6:41)

Updates in the use of neratinib in fibrolamellar carcinoma and biliary tract cancer

(2:21)

ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancer

(53)

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

(8:33)

Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer

(1:57)

Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

(1:40)

Dr. Lin on CNS-Specific Outcomes With Neratinib in HER2+ Breast Cancer

(1:14)

Dr. Blackwell on Neratinib in HER2+ Breast Cancer

(1:44)

Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain Metastases

(5:21)